The presence of internal tandem duplications (ITD) mutations in the FMS-like tyrosine kinase 3 (FLT3) receptor influences the risk of relapse in acute myeloid leukaemia (AML). We have investigated DNA repair in FLT3-ITD and wild-type (WT) cells. Using the comet assay, we have demonstrated that the FLT3 inhibitor PKC412 significantly inhibits repair of DNA damage in the MV4-11-FLT3-ITD cell line and FLT3-ITD patient samples but not in the HL-60-FLT3-WT cell line or FLT3-WT patient samples. Following the discovery that transcript levels of the DNA repair gene RAD51 are significantly correlated with FLT3 transcript levels in FLT3-ITD patients, we further investigated the role of RAD51 in FLT3-ITD-AML. The reduction in DNA repair in PKC412-treated FLT3-ITD cells was shown to be associated with downregulation of RAD51 mRNA and protein expression and correlates with the maintenance of phosphorylated H2AX levels, implying that PKC412 inhibits the homologous recombination double-strand break repair pathway in FLT3-ITD cells. Using FLT3-short interfering RNA (siRNA), we also demonstrated that genetic silencing of FLT3 results in RAD51 downregulation in FLT3-ITD cells but not in FLT3-WT cells. This work suggests that the use of FLT3 inhibitors such as PKC412 may reverse the drug-resistant phenotype of FLT3-ITD-AML cells by inhibiting repair of chemotherapy-induced genotoxic damage and thereby reduce the risk of disease relapse.
Introduction
Acute myeloid leukaemia (AML) is a clonal haematopoietic disorder that is frequently associated with genetic instability characterized by a diversity of chromosomal and molecular changes. Many of these changes can be detected by the presence of abnormal karyotypes following cytogenetic analysis: abnormalities are found in more than 50% of AML patients. 1 DNA repair mechanisms play a vital role in maintaining genetic integrity, and abnormally low levels of repair may result in disease pathogenesis. In contrast, elevated levels of DNA repair can inhibit the apoptosis pathway and enable a cell with badly damaged DNA to attempt repair, potentially mis-repair and survive. This aspect of aberrant DNA repair also has major implications in cancer and leukaemia biology by conferring resistance to therapy on malignant cells, which is a phenotype seen in many AML patients. In this setting, inhibition of DNA repair would be proposed to enhance the efficacy of genotoxic chemotherapeutic agents, thus resulting in more favourable patient outcomes.
FLT3 is a member of the class III receptor tyrosine kinase family, and the presence of internal tandem duplication (ITD)-activating mutations in the FLT3 receptor occur in approximately 25% of AML patients. [2] [3] [4] FLT3 mutations result in constitutive activation of the receptor and downstream activation of signalling pathways. Aberrant signalling in FLT3-ITD cells has been demonstrated to occur via a number of pathways including signal transducers and activators of transcription 5 (STAT5), mitogen-activated protein (MAP) kinase and phosphatidylinositol 3 (PI3) kinase pathways. 5, 6 These signalling pathways give rise to the FLT3-ITD phenotype by influencing a large number of genes and proteins. Clinically, the presence of FLT3 mutations confers an adverse prognosis in AML primarily owing to an increased risk of disease relapse resulting in a lower overall survival. 3, 4 The precise mechanisms underlying the increased risk of disease relapse are currently unclear.
The identification of FLT3 as a molecular target has focused efforts towards the development of drugs to inhibit activated FLT3 receptor-mediated signalling, and a number of clinical trials are currently underway. One of these inhibitors is PKC412, which has been shown to demonstrate inhibitory activity to a number of class III tyrosine kinase receptors including FLT3. 7 A recent publication described encouraging results following a phase 2 trial of PKC412 in advanced AML and myelodysplastic syndrome patients whose cells had activating FLT3 mutations. 8 The oncogenic tyrosine kinase BCR/ABL has previously been shown to increase levels of RAD51 via the activation of STAT5 in chronic myeloid leukaemia (CML) cells.
9 RAD51 is a key protein in the high-fidelity homologous recombination (HR) double-strand break (DSB) repair pathway and is the limiting factor for this pathway in mammalian cells. 10 Overexpression of RAD51 has been observed in a wide range of malignant cell lines including AML cell lines 11 and there are several reports in the literature examining the levels of RAD51 in patients with a variety of different cancers. [12] [13] [14] More recently, RAD51 has been shown to be increased in haematopoietic murine cells engineered to express dual FLT3-ITD and tyrosine kinase domain (TKD) mutants. 15 Overexpression of RAD51 is functionally significant because it causes elevated rates of HR and subsequent genomic instability. [16] [17] [18] High levels of HR activity have been shown to be associated with increased resistance to a number of different genotoxic therapies. 12, 14, 17 Conversely, if the levels of RAD51 are downregulated, cells become sensitive to cytotoxic therapy. 19, 20 The present study was undertaken in order to examine the relationship between FLT3-ITDs and DNA repair in AML.
Materials and methods

Patient samples and cell lines
Blood or bone marrow samples were obtained at diagnosis from patients with AML following informed consent according to the Declaration of Helsinki Principles, samples from all FrenchAmerican-British types except M3 were collected and the patients had a median age of 66 years. Blast cells were separated, frozen and thawed as described previously. 21 All of the patient samples used in the DNA repair assays, for whom cytogenetic information was available, had normal karyotypes to reduce the possibility of competing genetic abnormalities that may influence DNA repair.
MV4-11 (ATCC:
LGC Promochem, Teddington, UK) is an AML cell line with a 30-base-pair homozygous FLT3-ITD, whereas HL-60 (ECACC, Salisbury, UK) expresses a low level of WT FLT3. Both cell lines were maintained in Rosewell Park Memorial Institute (RPMI)-1640 medium with 10% foetal calf serum (FCS) and 1% glutamine.
FLT3 mutation analysis
Genomic DNA was extracted from samples using a QIAamp blood DNA isolation kit (Qiagen, Crawley, UK) according to the manufacturer's protocol. Approximately 100 ng of genomic DNA was used as template in PCR analysis to amplify exons 14 and 15 and the intervening intron of the FLT3 gene using previously described primers. 22 Samples were also analysed for the presence of a point mutation in the tyrosine kinase domain at codon position 835(Asp), 23 samples with this mutation were not studied further and therefore, for the purpose of this work, FLT3-WT denotes samples with neither an ITD nor an Asp835 mutation.
Alkaline comet analysis
All patient samples analysed using the comet assay were cryopreserved. Subtoxic doses of PKC412 (a kind gift from Novartis, Basel, Switzerland) and daunorubicin (Cerubidin, Rhone-Poulenc Rorer, West Malling, UK) were determined for each patient sample before comet analysis; this was established as the highest dose to produce 20% loss of viability after 24 h (as measured by the Trypan blue exclusion assay). For the DNA damage/repair analysis, cells were thawed as described, resuspended in culture medium at a concentration of 5 Â 10 5 cells/ml and incubated for 24 h7PKC412. Daunorubicin was then added for 1 h. Cells were washed twice at 41C in RPMI-1640 and electrophoresed (t ¼ 0) or allowed to repair. Trevigen (AMS Biotechnology Ltd, Abingdon, UK) comet assay slides and lysis buffer were used for the comet assay and the protocol was followed according to the manufacturer's instructions. Slides were stained with 2.5 mg/ml propidium iodide (Sigma-Aldrich, Poole, UK) and images were visualized under a rhodamine filter with an Olympus BX40 microscope and the comets were analysed using Comet Assay III image analysis software (Perceptive Instruments, Suffolk, UK). Fifty comet images were obtained from each of the duplicate gel spots and each experimental condition was repeated; therefore, 200 images were scored in total for each treatment. The Tail Moment was used in all analysis and for the purpose of this work loss of damage over time was referred to as DNA repair.
Quantitative PCR
RNA was prepared from blast cell preparations using the QIAamp RNA kits with DNase treatment according to the manufacturer's instructions (Qiagen). Up to 2 mg of RNA was used in a reverse transcription reaction with Moloney murine leukaemia virus (MMLV) reverse transcriptase (Invitrogen, Paisley, UK) and random hexamers (GE Healthcare, Little Chalfont, UK). Quantitative PCR was performed on an ABI prism 7700 (Applied Biosystems, Warrington, UK) using Excite Real Time Mastermix with sybr green (Biogene, Cambridge, UK). Thermal cycler conditions included incubation at 951C 10 min, followed by 40 cycles of 951C 15 s and 601C 1 min. Following the 40 cycles, the products were heated from 60 to 951C over 20 min to allow melting curve analysis to be performed. This allowed the specificity of the products to be determined (single melting peak) and confirmed the absence of primer-dimers.
To enable the levels of transcripts to be quantified, standard curves were generated using serial dilutions of KG1a cDNA for RAD51 analysis and MV4-11 cDNA for FLT3 analysis. The housekeeping gene b-2-microglobulin (b2M) was used to standardize the samples and the relative expression levels of RAD51 and FLT3 transcripts were therefore calculated as the ratio between the level of RAD51 or FLT3 and the level of b2M. ). Negative controls (no template) were included in each experiment and all reactions were run in triplicate.
Western blotting
Cell pellets from 5 Â 10 6 cells were resuspended in 250 ml cell lysis buffer (50 mM Tris-HCl, pH 6.8, 150 mM NaCl, 1% Triton X-100, 0.1% sodium dodecyl sulphate (SDS), 10 mM ethylenediaminetetraacetic acid (EDTA), 0.5% deoxycholic acid, phenylmethylsulphonyl fluoride (PMSF) (1 mM), aprotinin (2.5 mg/ml), leupeptin (2.5 mg/ml)) and sonicated. The protein concentration of supernatants was determined using BioRad protein assay reagent (Bio-Rad, Hemel Hempstead, UK) to allow for equal loading of 40 mg/sample. Cell lysates were resolved on a 4% stacking, 10% resolving SDS-polyacrylamide gel electrophoresis (PAGE) gel. Following electrophoresis, gels were electroblotted onto a Hybond-P polyvinylidene fluoride (PVDF) transfer membrane (GE Healthcare). Nonspecific sites on the membrane were blocked using 5% non-fat milk and membranes were probed with either 2 mg/ml mouse monoclonal anti-RAD51 (Abcam (ab123), Cambridge, UK), 0.4 mg/ml rabbit polyclonal anti-FLT3 (Santa Cruz sc-480; Autogen Bioclear, Calne, UK) or 0.4 mg/ml mouse monoclonal anti-Actin (Santa Cruz sc-8432) followed by goat anti-mouse-or rabbit-HRP (BD Biosciences, Oxford, UK). Antibody binding was visualized by chemiluminescence (GE Healthcare).
Flow cytometry Phosphorylated STAT5. Phosphorylated STAT5 was measured on a semiquantitative scale using flow cytometry. The method used has previously been explained in detail by Pallis et al.
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Phosphorylated H2AX. Primary AML cells were incubated at 5 Â 10 5 /ml for 24 h in 5% CO 2 at 371C with or without 0.1 mM PKC412 in culture medium. They were then incubated for a further 1 h with or without 25 mg/ml etoposide, followed by two rinses in ice-cold RPMI-1640. A portion of the cells were then fixed immediately in order to assess baseline damage, and a portion was resuspended in fresh culture medium and returned to the incubator to allow time for repair to take place. Cells were harvested and fixed after 40 min for further incubation. H2AX phosphorylation was measured with a kit from Upstate (Dundee, UK) according to manufacturer's instructions.
siRNA nucleofection. siRNA (Hs_FLT3_2_HP, 1423109; control siRNA, 1022076, Qiagen) was introduced into 4 Â 10 6 cells in logarithmic growth phase using nucleofection (Amaxa GmbH, Cologne, Germany). Cells were nucleofected according to the manufacturer's guidelines; solution R (Amaxa) and program X-001 were used for the MV4-11 cell line and solution V (Amaxa) and program T-019 were used for HL-60 nucleofection.
Statistical analysis
Statistical analysis was carried out using the Statistical Package for Social Sciences, version 9 (SPSS, Chicago, IL, USA). P-values of less than or equal to 0.05 were considered to represent significance.
Results
FLT3-ITD cells have a DNA repair pathway that can be inhibited by PKC412
We adopted the comet assay to examine the effect of the anthracycline daunorubicin, a drug commonly used in AML therapy and an inducer of DSBs, on DNA repair in the presence or absence of the FLT3 inhibitor PKC412 on the cell lines MV4-11 and HL-60 and also on patient cell samples. Before the treatment of cells with PKC412 and daunorubicin, minimally toxic doses of both drugs (i.e. doses that induced o20% apoptosis) were determined for each patient and cell line. The doses used were in the range of 0.05-0.1 mM PKC412 and 0.05-0.5 mg/ml daunorubicin. These doses of PKC412 were also demonstrated to be biologically active in randomly selected samples by decreasing STAT5 phosphorylation as measured by our quantitative assay (data not shown).
The MV4-11 and HL-60 cell lines were treated with the FLT3 inhibitor PKC412 for 24 h and then exposed to daunorubicin for 1 h. As shown in Figure 1 , the MV4-11 FLT3-ITD cell line, but not the FLT3-WT HL-60 cell line, demonstrated a statistically significant loss of DNA repair when treated with PKC412 and daunorubicin (Mann-Whitney U-test at t ¼ 40; Po0.001). Comet assays were also performed on 11 patient samples (five FLT3-WT, six FLT3-ITD) and similar effects were demonstrated, with a loss of DNA repair in the FLT3-ITD cells in the presence of PKC412, whereas no loss of repair was observed in the FLT3-WT cells (Figure 2 ). These assays were generally performed on patient samples before FLT3 mutation status had been determined and therefore the assays were effectively performed blinded.
RAD51 gene expression levels correlate with expression levels of FLT3 in ITD cells
Mouse BaF3 cells expressing an FLT3 construct with a dual ITD/ TKD mutation have been shown to harbour upregulated RAD51. 15 We therefore quantified RAD51 and FLT3 transcript expression by real-time PCR from a large number of AML patient samples (FLT3-WT n ¼ 54; FLT3-ITD n ¼ 27). The level of RAD51 transcripts was significantly correlated with the level of FLT3 transcripts in FLT3-ITD cells (Spearman's; P ¼ 0.008), but not in FLT3-WT cells (Figure 3a) . As the presence of an FLT3-ITD has the most pronounced adverse clinical impact in patients with normal cytogenetics, we analysed the subset of patients with this karyotype separately. We found that the strength of the correlation was particularly prominent in those patients with FLT3-ITD mutations but otherwise normal karyotypes (Spearman's, P ¼ 0.002) (Figure 3b ).
PKC412 treatment of FLT3-ITD cells results in decreased expression of RAD51
We next examined whether the decrease in DNA repair in FLT3-ITD cells exposed to PKC412 was related to a reduction in RAD51 expression. We established a time course of RAD51 transcript levels in MV4-11 and HL-60 cells following incubation in the presence or absence of PKC412 for up to 24 h. Figure  4a and b demonstrates that MV4-11 FLT3-ITD cells express a higher level of basal RAD51 compared to HL-60 FLT3-WT cells and clearly illustrate a downregulation of RAD51 mRNA expression during PKC412 treatment; the levels in the FLT3-WT cell line remain relatively constant. RAD51 protein was also confirmed to be downregulated in PKC412-treated MV4-11 cell line by Western blotting, but RAD51 protein levels in the HL-60 cell line remained unchanged (Figure 4c ). 
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We subsequently studied RAD51 transcript levels in primary AML cells from patients7PKC412. There was a statistically significant decrease in RAD51 transcript level following PKC412 treatment in the FLT3-ITD samples but not in the FLT3-WT samples. Figure 5 demonstrates that RAD51 transcript levels are reduced in 8/12 (67%) of FLT3-ITD samples following PKC412 treatment, whereas this occurs only in 2/11 (18%) of FLT3-WT samples (Mann-Whitney U-test; P ¼ 0.03).
PKC412 inhibits the loss of gH2AX in etoposide-damaged FLT3-ITD patient cells
The alkaline comet assay detects single-strand breaks and alkaline-labile sites as well as DSBs, whereas RAD51 mediates DSB repair only. Therefore, to establish whether the decrease in DNA repair seen following PKC412 treatment of FLT3-ITD patient samples in the comet assay can be attributed to DSB repair, we measured the levels of phosphorylated H2AX (gH2AX) in two FLT3-ITD and two FLT3-WT patient cell samples. H2AX is phosphorylated at the sites of DSBs and the level of gH2AX has been shown to give a sensitive and accurate estimation of the number of DSBs within DNA. 27, 28 In addition, the loss of gH2AX has been shown to closely correlate to DSB PKC412 inhibition of DNA repair in FLT3-ITD AML cells CH Seedhouse et al repair. 27 We adopted a semiquantitative flow cytometry assay to measure gH2AX and followed its loss as a means of measuring DSB repair in patient cells. Etoposide was chosen as the DNAdamaging agent in these experiments because it is a particularly good inducer of DSBs, thereby resulting in sufficient gH2AX to allow its quantification. Following treatment of FLT3-WT patient cells with etoposide, there was no loss of gH2AX after 40 min, indicative of a lack of repair of DSBs within this time period. However, the two FLT3-ITD AML samples demonstrated a significant loss of gH2AX over the same time period, indicative of an active DSB repair pathway in these samples. Furthermore, the reduction in levels of gH2AX over time in the FLT3-ITD samples could be totally inhibited by PKC412. These results strongly suggest that PKC412 inhibits DSB repair in FLT3-ITD patient samples. These results are summarized in Table 1 .
STAT5 phosphorylation is associated with RAD51 gene expression in FLT3-ITD samples
Murine cell lines transfected with FLT3-ITDs have previously been shown to exhibit constitutive phosphorylation of STAT5, which is not seen following transfection of the FLT3-WT gene. 5, 6 The promoter region of RAD51 has recently been fully analysed and STAT5 has been shown to be involved in the transcriptional regulation of the RAD51 gene. 29 We therefore used a semiquantitative flow cytometry assay to measure the level of phosphorylated STAT5 in AML patient samples. In FLT3-ITD samples, there was an association between STAT5 phosphorylation and RAD51 transcript levels, which is verging on statistical significance and suggests that activated STAT5 contributes to RAD51 upregulation in FLT3-ITD samples (Spearman's rho correlation, one-tailed test, P ¼ 0.082). This trend was not seen with the FLT3-WT samples; in fact, low levels of STAT5 phosphorylation were associated with the highest levels of RAD51, implying a totally different mechanism of RAD51 regulation in this patient group (Figure 6 ).
RAD51 is downregulated in the FLT3-ITD MV4-11 cell line but not in the FLT3-WT HL-60 cell line following treatment with FLT3-siRNA To determine that the downregulation of RAD51 by PKC412 was dependent on FLT3-ITD, MV4-11 and HL-60 cell lines were nucleofected with either control (non-silencing) or FLT3-siRNA. Levels of FLT3 and RAD51 were assayed by real-time polymerase chain reaction (PCR) and Western blotting after 24 h. Figure 7 demonstrates that downregulation of FLT3 by FLT3-siRNA in MV4-11 cells results in a decrease in RAD51 mRNA and protein levels, this was not seen in the HL-60 and FLT3-WT cells, demonstrating that the RAD51 effect is specific to FLT3-ITD.
Discussion
The presence of an FLT3-ITD is associated with a high risk of disease relapse in AML. An enhanced ability to survive genotoxic exposure might explain this clinical observation, leading us to focus on the DNA repair process in FLT3-ITD cells. Figure 6 Association between phosphorylated STAT5 expression and RAD51 transcript levels in FLT3-ITD and FLT3-WT AML patient samples. STAT5 phosphorylation was measured using flow cytometry and RAD51 transcript levels were measured using real-time PCR and were standardized to b2M gene. The bold line illustrates the association between STAT5 phosphorylation and RAD51 transcripts in the FLT3-ITD patients (n ¼ 22), whereas the dotted line refers to the association in the FLT3-WT patients (n ¼ 24).
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DNA repair is an established mechanism of drug resistance and we therefore propose that increased DNA repair in FLT3-ITD cells contributes to the risk of disease relapse by allowing damaged leukaemic cells to repair their genome, survive and mediate relapse. This is supported by the fact that FLT3-ITDs are present in leukaemic stem cells 30 and also that FLT3-ITD mutations are found in diagnostic and relapsed paired samples and accumulate during disease progression. 31 Inhibition of DNA repair with FLT3 inhibitors in FLT3-ITD AML patients would be proposed to reduce the risk of disease relapse by impairing the ability of leukaemic cells to survive chemotherapy-induced DNA damage without undergoing apoptosis.
Following previous reports indicating the importance of the role of RAD51 in leukaemic cells, 9, 15 we examined the expression of FLT3 and RAD51 transcripts in a large number of AML samples. We demonstrated a significant association between FLT3 and RAD51 transcripts in FLT3-ITD samples, particularly in the FLT3-ITD/normal cytogenetics subgroup, and it is possible to speculate that the FLT3-ITD mutations may have most impact in the absence of competing genetic abnormalities that may also influence the expression of RAD51. Similar to observations in CML 9 and BaF3 murine cells transfected with FLT3-ITD/TKD double mutations, 15 we found that the level of RAD51 in primary AML patient samples is related to STAT5 phosphorylation, although this association was not statistically significant. Primary patient AML samples contain heterogeneous populations of cells harbouring many mutations and it is likely that while phosphorylated STAT5 upregulates RAD51, other signalling pathways also contribute to RAD51 upregulation. Further work is required to determine the identity of other pathways that contribute to FLT3-ITD-mediated upregulation of RAD51.
The role of RAD51 and DSB repair was further implicated in FLT3-ITD AML by the demonstration that FLT3-ITD inhibition by PKC412 resulted in a reduction of RAD51 transcript and protein levels. This led us to adopt a more specific assay for the measurement of DSB repair. For this purpose, we measured gH2AX, one of the earliest molecular events following the formation of DSBs. FLT3-ITD patient samples rapidly lost gH2AX, indicative of enhanced DSB repair; this was not seen in FLT3-WT cells. The inhibition of gH2AX loss (no DSB repair) by PKC412 confirmed the DSB repair pathway as a downstream target of FLT3 inhibitors.
Following PKC412 treatment, four out of the 12 FLT3-ITD samples did not demonstrate any decrease in RAD51 levels. AML is a heterogeneous disease and a large number of signalling pathways are dysregulated. Although we have examined FLT3-ITDs in our patient cells, it is possible that RAD51 expression may be affected by other activating mutations and that other signalling pathways may over-ride those from FLT3 activation. In addition, we suggest that FLT3-WT cells may have different biological mechanisms controlling RAD51 expression. This is supported by our comet, RAD51 expression and STAT5 measurements (Figures 2, 5 and 6 ). In several of the FLT3-WT AML samples, there appeared to be an antagonistic effect of PKC412 with respect to RAD51 expression and DNA repair and the mechanisms responsible for RAD51 regulation in FLT3-WT AML certainly warrant further investigation. It should be noted that an antagonistic effect in FLT3-WT samples treated with PKC412 and daunorubicin has been shown previously (Mollgard et al. Blood 2004; 104: 1810A). It is currently not known whether these antagonistic effects may be specific to PKC412 or whether they may occur with other FLT3 inhibitors. Such results have important clinical implications and suggest that patients should be screened to determine their FLT3 mutational status before FLT3 inhibitors are given in combination with chemotherapeutic agents. A further clinical consideration is the administration sequence of FLT3 inhibitor and drugs. The results described here imply that downregulation of RAD51 (by FLT3 inhibition) would be advantageous before DNA damage occurs via the genotoxic agent.
To demonstrate that the effects on RAD51 levels were not specific to PKC412, we downregulated FLT3 using siRNA. The assays demonstrated that whereas FLT3-siRNA treatment resulted in decreased FLT3 transcripts and protein in both MV4-11 and HL-60 cell lines, only the FLT3-ITD-containing MV4-11 cells had an associated decrease in RAD51 transcripts and protein. These results strongly imply that RAD51 is a target specifically in FLT3-ITD cells, but not in FLT3-WT cells.
In summary, our results demonstrate that FLT3-ITD mutations are associated with enhanced DNA DSB repair. This increase in DNA repair may contribute to the high incidence of relapse seen in FLT3-ITD AML by enhancing repair of potentially lethal DNA damage caused by chemotherapy drugs. The FLT3 inhibitor PKC412 has been shown to inhibit DSB repair in FLT3-ITD cells and also to downregulate the DNA repair gene RAD51. The FLT3-ITD specificity of RAD51 downregulation was confirmed using genetic means by silencing FLT3 with siRNA: only the FLT3-ITD cell line displayed a decrease in RAD51 levels. The use of FLT3 inhibitors concurrent with chemotherapy is therefore proposed to result in enhanced leukaemic cell kill and reduce the relapse risk of AML with FLT3-ITDs. 
